229eP Cardiotoxicity of checkpoint inhibitor immunotherapy (ICI) in renal cell carcinoma (RCC): Real world evidence from ARTIST study
ICIs have transformed RCC treatment. Although rare, incidence around 1%, ICI-related cardiac toxicities can be fatal. This single-centre study aim to assess the real-world prevalence, outcomes, and risk factors for ICI cardiotoxicity.
Authors
- M. Cheang
- K. Fife
- B. O'Carrigan
- J. Jones
- M. Hussein Ismail
- R. Shawky
- H.M.A. Abdallah
- W. Ince
Institutions
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Cambridge School (PT)
- Bridge University (SS)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101312
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00